Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis ... network that constantly scans and repairs a cell’s genome.2 PARP1 is one of the first responders to damaged DNA, and its importance is ...

Figure 1: Domain architecture of the classic poly-ADP-ribose-polymerase PARP1 and the newly characterized mono-ADP-ribosyltransferase PARP10. Figure 2: Classification of the poly-ADP-ribose ...

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced that it has engaged Shareholder ...